The Value of Adjuvant Radiotherapy in Pulmonary and Chest Wall Resection for Bronchogenic Carcinoma
|
|
- Victor Roberts
- 5 years ago
- Views:
Transcription
1 The Value of Adjuvant Radiotherapy in Pulmonary and Chest Wall Resection for Bronchogenic Carcinoma G. A. Patterson, M.D., R. Ilves, M.D., R. J. Ginsberg, M.D., J. D. Cooper, M.D., T. R. J. Todd, M.D., and F. G. Pearson, M.D. ABSTRACT Thirty-five patients, 29 men and 6 women, underwent pulmonary and chest wall resection for treatment of bronchogenic cancer which had extended into the chest wall. Anterior chest wall resection was performed in 6 patients, lateral resection in 2, and posterior resection in 27. Marlex mesh was employed as a prosthetic material in 13 patients. Radiotherapy was given as part of the planned therapeutic regimen in 13 patients. Three patients (8.5%) died in the postoperative period. There were 21 late deaths. Eleven patients are alive 7 months to 12 years after resection. The overall actuarial survival, including operative mortality, is 38% at 5 years. Actuarial survival of the 13 irradiated patients is 56% at 2 and 5 years. We believe that bronchogenic carcinoma with chest wall involvement is not hopeless, and that resection of the lung and chest wall can be performed with an acceptable mortality rate. The chest wall is involved by direct tumor extension in approximately 2 to 8% of patients undergoing thoracotomy for bronchogenic cancer [l-31. Until the report by Coleman [4] in 1947 of 2 long-term survivors among 5 patients undergoing combined resection, it was generally believed that chest wall involvement with lung cancer indicated a uniformly dismal prognosis. Since then, a number of series have supported combined resection of chest wall and lung for such pulmonary tumors. The role of adjuvant radiotherapy, however, is controversial. In a small number of patients, surgeons at the Mayo Clinic considered radiotherapy to be of no value [2]. However, Mishina and coworkers [31 recently reported increased long- From the Thoracic Surgical Group, Toronto General Hospital, Toronto, Ontario, Canada. Presented at the Eighteenth Annual Meeting of The Society of Thoracic Surgeons, Jan 11-13, 1982, New Orleans, LA. Address reprint requests to Dr. Ilves, Toronto General Hospital, Eaton Wing N , Toronto M5G 1L7, Canada. term survival with adjuvant radiotherapy or radiotherapy combined with chemotherapy. The present study reviews our results with combined pulmonary and chest wall resection, and attempts to clarify the role of adjuvant radiotherapy. Patients and Methods Between September, 1969, and January, 1981, 35 patients underwent resection of the lung and chest wall for treatment of bronchogenic cancer, which had extended both grossly and microscopically into the chest wall. In all patients, the tumor had extended through the parietal pleura by microscopy and, in most, into the musculoskeletal chest wall as well. Patients with tumors extending through the mediastinum, pericardium, or diaphragm were excluded from this study. Patients with superior sulcus tumors were also excluded. Clinical Findings PATIENT POPULATION. There were 29 men and 6 women. The mean age was 64 years, with a range of 53 to 81 years. The most common symptom seen was chest pain, which was present in 26 patients (74%). All patients had clearly demonstrable lesions on chest roentgenograms. Special rib views and laminagrams were used in 20 patients and showed definitive evidence of chest wall invasion in 9. The CAT scan, which was used once, also defined invasion. OPERATIVE PROCEDURES. Twenty-six patients underwent a single lobectomy, 2 had a bilobectomy, 1 had a lobectomy with a wedge resection, 5 had a pneumonectomy, and 1, an isolated wedge resection (Table 1). The number of ribs involved in the resection is shown in Table 2. Three ribs were resected most frequently (18 patients). Anterior chest wall resection was performed in 6 patients, lateral resection, in 2 patients, and posterior resection, in by The Society of Thoracic Surgeons
2 693 Patterson et al: Adjuvant Radiotherapy after Pulmonary and Chest Wall Resection Table 1. Operative Procedures in 35 Patients Undergoing Pulmonary and Chest Wall Resection for Bronchogenic Carcinoma Procedure Lobectomy 26 Bilobectomy 2 Lobectomy + wedge resection 1 Pneumonectomy 5 Wedge resection 1 Total 35 No. of Patients Table 2. Number of Ribs Resected in Operations for Bronchogenic Carcinoma No. of Ribs No. of Patients patients. In 29 resections, the pulmonary and chest wall specimens were removed en bloc. Resection was believed to be curative in 30 patients and palliative in 5 others, who had tumor involvement at the resection margins or the highest removed lymph node. Marlex mesh, the only prosthetic material used, was employed in a single layer in 8 patients and in a double layer in 5 patients. Pathological Findings The distribution of tumor cell types is shown in Table 3. The most frequently observed tumor was squamous cell carcinoma in 27 patients. By definition, these tumors are all classified as T3. Twenty-four patients had NO lesions, 6 patients had N1 lesions, and N2 disease was found in 5 patients. Adjunctive Therapy Radiotherapy was part of the planned therapeutic regimen in 13 patients. Five patients were irradiated preoperatively and 8, postoperatively. In 2 patients, radiation was utilized because of known residual chest wall Table 3. Cell Types and Staging of Tumors in Bronchogenic Carcinoma Seen in 35 Patients Characteristic Cell type Squamous cell 27 carcinoma Adenocarcinoma 5 Large cell carcinoma 1 Mixed cellularity 1 Unspecified 1 Total 35 Staging T3NO T3N1 T3N2 Total No. of Patients involvement. In another 2 patients, radiation was added because of mediastinal node involvement, which was grossly removed. In the other 9 patients, there was no particular bias for adjuvant therapy other than the surgeon's preference. The dose of radiation ranged from 2,000 to 5,000 rads, averaging 3,464 rads. Twenty-two patients were not irradiated. Chemotherapy was not used as part of the initial therapy in any patient. Results Three patients died in the postoperative period, for an operative mortality of 8.5%. Respiratory failure was the major precipitating event in all deaths. A lobectomy was done in 2 of these patients, 1 of whom was reconstructed with single-layer Marlex mesh. The third patient had a pneumonectomy, also with single-layer Marlex reconstruction. Chest wall instability was not thought to contribute to the respiratory failure. Two of the patients who died also had extensive mediastinal dissection for N2 nodes. Eleven patients are alive seven months to 12 years postoperatively (follow-up as of August, 1981). The overall actuarial survival, including operative mortality, is 38%. Two patients are alive with known metastatic disease. No survivors have locally recurrent disease in the chest wall. All 21 late deaths occurred from dis-
3 694 The Annals of Thoracic Surgery Vol 34 No 6 December I TIME SINCE SURGERY (YRS) Actuarial survival for chest wall resection. Radiated) (Combined) (Non-rodialedl seminated metastatic disease. There are no survivors among 5 patients with N2 disease. Only one of 6 patients with N1 disease is alive (at 2 years) with known metastatic disease. Of 22 patients not irradiated, only 4 remain alive (survival range, 2 to 8 years). One of these is the single N1 survivor. Actuarial survival is 36% at 2 years and 30% at 5 years (see Figure). Of 13 patients who received radiation, 7 are alive. This number includes 2 of 5 patients irradiated preoperatively and 5 of 8 patients irradiated postoperatively. Actuarial survival for irradiated patients is 56% at 2 years and 56% at 5 years. In the irradiated group, 2 patients had palliative, incomplete resections and N1 lesions; 2 other patients had N2 lesions. This leaves 9 irradiated patients with T3NO lesions and curative resections. Seven of the 9 (78%) are alive and free of disease. Of 14 patients who were not irradiated and who also had T3NO lesions and curative resections, only 3 (21%) are alive (Table 4). Local chest wall recurrence did not develop in any irradiated patient. Among the 22 patients who were not irradiated, 6 (27%) developed locally recurrent disease. Five patients had incomplete resections; 2 of these had postoperative irradiation. There were no survivors in this group, but local recurrence was seen in only 1 nonirradiated patient who also had hematogenous metastases. Atelectasis of a lung or lobe was the most frequent complication, occurring in 10 patients. Five of these patients had Marlex reconstructions. Respiratory failure, requiring mechanical ventilatory support for more than 24 hours, was seen in 6 patients. Two patients developed wound infections, and 2 others developed late postoperative empyema, necessitating removal of the Marlex mesh; 1 of these patients had developed a late bronchopleural fistula. Most of the patients were relieved of their chest wall pain, but 3 developed intractable postthoracotomy discomfort. In no patient was late chest wall instability a symptomatic problem. Comment Our experience confirms earlier reports of the value of surgical resection for carcinoma of the lung involving the chest wall. The actuarial survival for the patients in our series was 38% at 5 years. Previous studies have also stated that the general use of adjuvant radiotherapy preoperatively is of no value [5]. However, Paulson [6] has demonstrated the benefit of preoperative radiotherapy in patients with superior sulcus tumors. Some reports have agreed that preoperative radiotherapy is beneficial [7], while others have disagreed [S]. In tumors involving Table 4. Follow-up Results in Patients Having Curative Resections (Excluding Operative Mortality) Irradiated Patients Nonirradiated Patients Staging of Tumor No. of Survivors No. of Deaths No. of Survivors No. of Deaths T3NO T3N la 1 T3N Total With known metastases. bexcluding 1 operative death.
4 695 Patterson et al: Adjuvant Radiotherapy after Pulmonary and Chest Wall Resection the nonapical chest wall, the role of adjuvant radiotherapy is unclear. Mishina and colleagues [3] suggest that adjuvant radiotherapy does improve survival, but the number of patients in their series was small, and in some patients adjuvant chemotherapy was also used. Geha and associates [2] believed that postoperative radiotherapy was of no benefit. In our series, there was an appreciable difference in 5-year actuarial survival between the nonirradiated and irradiated groups: 30% and 56%, respectively. This difference is even more marked when comparing curative resections for T3NO disease. In the irradiated group, the 5-year actuarial survival was 69%, including one operative death. It should be stressed that the two groups were similar in all respects, and that adjuvant radiotherapy was used according to the surgeon's preference. There was no statistically significant difference in actuarial survival during the 5-year postoperative period between the irradiated and nonirradiated groups (p = 0.1). This could be because of the small number of observations involved. Radiotherapy seems to diminish the incidence of local recurrence. Among 12 irradiated operative survivors in our series, none developed chest wall recurrence. In contrast, among 20 nonirradiated operative survivors, 6 developed locally recurrent disease. As is generally recognized, nodal involvement portends an unfavorable prognosis. Geha and ass6'ciates [21 reported only 1 fiveyear survivor among 5 patients undergoing combined pulmonary and chest wall resection. Mishina and colleagues [31 also reported 1 five-year survivor among 10 patients with nodal involvement. These figures are somewhat lower than those generally reported for lung cancer [9]. However, they are consistent with our analysis. Only 1 of 6 patients with N1 disease is alive two years after operation, and none of 4 patients with N2 disease is alive. There are several statements in the literature that our study does not support. Jamieson and co-workers [lo] state that operative mortality and morbidity are lower with pneumonectomy than with lobectomy in this group. Lavenson and Serfas [ll] have even suggested that pneumonectomy should be the procedure of choice when a combined resection is required. Our results are not consistent with these views. The operative mortality for pneumonectomy was 1 in 5 patients (20%), and there were no survivors among the patients who underwent pneumonectomy. This finding is in agreement with others [2, 31, and reflects either a larger tumor or more extensive nodal involvement. It has also been stated that en bloc resection is mandatory [2]. Our figures suggest this is not the case. Of 6 patients undergoing discontinuous resection, 3 are alive. In such patients, the adherence of the lung to the chest wall must not be overly solid or extensive; however, 2 of these survivors did have microscopic invasion of the intercostal muscle. Mishina and associates [3] correlate the depth of chest wall invasion with the prognosis. The majority of patients undergoing chest wall resection do not require a prosthetic chest wall support. However, large resections, especially those in an anterior or lateral position outside the range of scapular cover, should be stabilized by means of a prosthesis. Many materials have been used successfully [lo, 12, 131. Ramsey and Cliffton 1121 reported a decrease in paradoxical motion, pneumonia, and scapular fixation in the thorax among their patients who received a prosthesis after chest wall and pulmonary resection. In our patients, Marlex mesh made no difference in the rate of atelectasis. The only two wound infections occurred in the absence of a prosthesis. Prosthetic materials are clearly of use in large defects. Our preference is to use Marlex mesh, as its pliability and ease of handling give it technical advantages. When the mesh is used in a double thickness with its fibers placed at 90" and under tension, almost complete resistance to stretching is obtained. Larger defects can be managed by using a "sandwich" composed of Marlex and methylmethacrylate, as described by McCormack and associates [13]. Our 8.5% operative mortality is consistent with that reported previously for these resections: 4% by Geha and colleagues [2], 9% by Grillo and associates [l], 15% by Ramsey and Cliffton [121, and 16% by Jamieson and associates [lo]. Respiratory failure was the major precipitating event in all our early deaths.
5 696 The Annals of Thoracic Surgery Vol 34 No 6 December Our conclusions from this study are: 11. Lavenson GS, Serfas LS: Advantage - of pneumonectomy in massive excision of the chest wall. Am J Surg 115:558, Ramsey HE, Cliffton EE: Chest wall resection for Chest wall involvement by bronchogenic carcinoma does not imply a hopeless prognosis. Resection of the lung and chest wall can be done with acceptable mortality and morbidity. Large portions of the chest wall can be resected using autogenous tissue or prosthetic material for reconstruction. There is no difference in survival between en bloc resection and discontinuous resection. Nodal status is a strong prognostic indicator. The use of adjuvant radiotherapy is favorable for long-term survival and lack of local recurrence. References 1. Grillo HD, Greenberg JJ, Wilkins EW: Resection of bronchogenic carcinoma involving the thoracic wall. J Thorac Cardiovasc Surg 51:417, Geha AS, Bernatz PE, Woolner LB: Bronchogenic carcinoma involving the thoracic wall: surgical treatment and prognostic significance. J Thorac Cardiovasc Surg 54:394, Mishina H, Suemash K, Yoneyama T, et al: Surgical pathology and prognosis of the combined resection of chest wall and lung in lung cancer. Jap J Clin Oncol8:161, Coleman FP: Primary carcinoma of the lung with invasion of the ribs: pneumonectomy and simultaneous block resection of the chest wall. Ann Surg 126:156, A Collaborative Study: Reoperative irradiation of cancer of the lung: final report of a therapeutic trial. Cancer 36:914, Paulson DL: Carcinomas in the superior pulmonary sulcus. J Thorac Cardiovasc Surg 70:1095, Attar S, Miller JE, Sattersfield J, et al: Pancoast s tumor: irradiation or surgery? Ann Thorac Surg 28:578, Kirsh MM, Dickerman R, Fayos J, et al: The value of chest wall resection in the treatment of superior sulcus tumors of the lung. Ann Thorac Surg 15:339, Wilkins EW, Scannell JA, Craver JG: Four decades of experience with resections for bronchogenic carcinoma at the Massachusetts General Hospital. J Thorac Cardiovasc Surg 76:364, Jamieson MPG, Walbaum PR, McCormack RJM: Surgical management of bronchial carcinoma invading the chest wall. Thorax 34:612, 1979 primary carcinoma of the lung. Ann Surg 167:342, McCormack P, Bains MS, Beattie EJ Jr, Martini N: New trends in skeletal reconstruction after resection of chest wall tumors. Ann Thorac Surg 31:45, 1981 Discussion DR. NAEL MARTINI (New York, NY): I have had the privilege of reviewing the manuscripts of Dr. Piehler and colleagues and Dr. Patterson and associates. The points of agreement seem to be that chest wall involvement does not necessarily imply an incurable situation, that complete resection is possible in some patients and that long-term survival is obtainable, particularly if the regional nodes are not involved. Histology does not seem to influence survival except in oat cell carcinoma. Despite the peripheral location of the tumors, epidermoid carcinoma seems to be the predominant histology observed in this group of patients. We agree that superior sulcus tumors do better and should be analyzed separately for survival. The paper of Dr. Piehler and his co-workers clearly addresses a purer group of patients since it excludes those having incomplete resections. En bloc resection, the recommended technique, is preferred but cannot always be done. The goal must be complete excision of all diseased tissue, with the assurance of microscopically clear margins of resection. Local recurrence and survival are influenced by the completeness of the resection. Even microscopic residual disease at the margins, so frequently a problem when extension to the spine is also present, adversely affects the survival. It is still unclear what the role of radiation should be in this group of patients. Although more local recurrence was observed by Dr. Patterson and his colleagues in patients who did not receive external radiation, no patient has apparently died because of local recurrence; all of the patients who have died have had disseminated disease. We observed no impact on survival with the use of preoperative or postoperative radiation therapy, particularly in patients with complete resection and no lymphatic metastasis. In the recent past, we irradiated 5 patients who had microscopic disease at the margins of resection despite complete excision of the entire gross tumor. None of these patients had lymphatic metastases, but all 5 have subsequently died. Three had massive local recurrences, despite irradiation. Moreover, involvement of the regional lymph nodes clearly poses a major prognostic risk, since only an occasional patient with N1 or N2 disease lives 3 or more years.
6 697 Patterson et al: Adjuvant Radiotherapy after Pulmonary and Chest Wall Resection There seems to be a particular tendency on the part of both studies to confine skeletal reconstruction to autologous tissue. We have converted to the routine use of Marlex mesh for skeletal reconstruction in nearly all our patients. The mesh is easy to apply and readily available, and it rarely causes infection that might warrant its removal. Finally, it is unclear from both studies how many patients had histological invasion of only the parietal pleura. In our experience, patients with only parietal pleural involvement do better than patients with pleural as well as skeletal and bone disease. We believe that the extent of tumor involvement and the completeness of the resection are the main determinants of survival in this group of patients. DR. MARCUS L. DILLON (Lexington, KY): We have been studying the effect of randomized postoperative radiation in our stage I and I1 cancer patients. The local recurrence rate has been very good in irradiated patients. However, the distant metastatic rate in these patients is 25% which is high compared with the local recurrence rate of 2%. The opposite is true in the nonirradiated patients. Although nothing is proved statistically because the number of patients is too small, we believe that irradiation may immunosuppress these patients, so that they tend to break out with distant metastases. Have you observed this phenomenon? DR. SALEM M. SAYEGH (New Orleans, LA): If irradiation is of value in these patients, would Dr. Patterson and his associates prefer preoperative irradiation, since the radiation affects only the lobe that is to be removed? With postoperative irradiation, the radiation affects the remaining lobes, and postoperative or radiation pneumonitis may result. DR. ALLEN J. TOGUT (Brockton, MA): Is there any experience with preoperative chemotherapy in these chest wall lesions? DR. RAYMOND DIETER (Glen Ellyn, IL): I would like to ask Dr. Patterson if he has any opinion as to why the cell type of the tumors did not make any difference in the results. DR. PATTERSON: We would like to thank Dr. Martini for his comments. I think everyone recognizes his group as a leader in the field of chest wall resection for cancer. Since most of our resections were posterior and seemed to be adequately covered by the scapula, we did not use Marlex mesh as often as Dr. Martini s group does. Regarding his points about locally recurring disease and survival, all of the patients who developed locally recurring disease in our group subsequently developed disseminated disease and died. None of the survivors have locally recurrent disease. Concerning Dr. Dillon s comments, we are not certain where his radiation site was. The only mediastinal radiation given in our series was to those patients who had N2 lesions. In response to Dr. Sayegh, I think we would irradiate a patient preoperatively if we knew for certain that the chest wall was involved, but I think in many instances one is not certain whether there is chest wall involvement prior to the thoracotomy. Dr. Togut, we did not use chemotherapy in any of our patients as part of their initial management. Needless to say, however, many of these patients who developed subsequent disseminated disease did undergo a course of chemotherapy. Dr. Dieter, we did not look at the influence of cell type in this series because of the preponderance of squamous cell tumors with the scattered appearance of a few other types. We very much appreciated listening to the report of Dr. Piehler and his colleagues, and I think that their statement of the purpose of their paper is essentially the same as ours. However, we also feel strongly that radiotherapy is of benefit.
The Role of Radiation Therapy
The Role of Radiation Therapy and Surgery in the Treatment of Bronchogenic Carcinoma R Adams Cowley, M.D., Morris J. Wizenberg, M.D., and Eugene J. Linberg, M.D. A study of the combined use of preoperative
More informationSignificance of Metastatic Disease
Significance of Metastatic Disease in Subaortic Lymph Nodes G. A. Patterson, M.D., D. Piazza, M.D., F. G. Pearson, M.D., T. R. J. Todd, M.D., R. J. Ginsberg, M.D., M. Goldberg, M.D., P. Waters, M.D., D.
More informationCarcinoma of the Lung
THE ANNALS OF THORACIC SURGERY Journal of The Society of Thoracic Surgeons and the Southern Thoracic Surgical Association VOLUME 1 I - NUMBER 3 0 MARCH 1971 Carcinoma of the Lung M. L. Dillon, M.D., and
More informationPrognostic Significance of Extranodal Cancer Invasion of Mediastinal Lymph Nodes in Lung Cancer
Jpn. J. Clin. Oncol. 198, 1 (), 7-1 Prognostic Significance of Extranodal Cancer Invasion of Mediastinal Lymph Nodes in Lung Cancer KEIICHI SUEMASU, M.D. AND TSUGUO NARUKE, M.D. Department of Surgery,
More informationCarcinoma of the Lung in Women
Carcinoma of the Lung in Marvin M. Kirsh, M.D., Jeanne Tashian, M.A., and Herbert Sloan, M.D. ABSTRACT The 5-year survival of 293 men and of 78 women undergoing pulmonary resection and mediastinal lymph
More informationTumour size as a prognostic factor after resection of lung carcinoma
Tumour size as a prognostic factor after resection of lung carcinoma A. S. SOORAE AND R. ABBEY SMITH Thorax, 1977, 32, 19-25 From the Cardio-Thoracic Unit, Walsgrave Hospital, Clifford Bridge Road, Coventry
More informationHISTORY SURGERY FOR TUMORS WITH INVASION OF THE APEX 15/11/2018
30 EACTS Annual Meeting Barcelona, Spain 1-5 October 2016 SURGERY FOR TUMORS WITH INVASION OF THE APEX lung cancer of the apex of the chest involving any structure of the apical chest wall irrespective
More informationSite of Recurrence in Patients. of the Lung Resected for Cure. with Stages I and I1 Carcinoma
Site of Recurrence in Patients with Stages I and I1 Carcinoma of the Lung Resected for Cure Steven C. Immerman, M.D., Robert M. Vanecko, M.D., Willard A. Fry, M.D., Louis R. Head, M.D., and Thomas W. Shields,
More informationRole of Surgery in Management of Non Small Cell Lung Cancer. Dr. Ahmed Bamousa Consultant thoracic surgery Prince Sultan Military Medical City
Role of Surgery in Management of Non Small Cell Lung Cancer Dr. Ahmed Bamousa Consultant thoracic surgery Prince Sultan Military Medical City Introduction Surgical approach Principle and type of surgery
More informationCHEST WALL INVASION IN NON SMALL CELL LUNG CARCINOMA: A RATIONALE FOR EN BLOC RESECTION
CHEST WALL INVASION IN NON SMALL CELL LUNG CARCINOMA: A RATIONALE FOR EN BLOC RESECTION Francesco Facciolo, MD a Giuseppe Cardillo, MD a Michele Lopergolo, MD a Guido Pallone, MD a Francesco Sera, DSc
More informationMediastinal Spread of Metastatic Lymph Nodes in Bronchogenic Carcinoma*
Mediastinal Spread of Metastatic Lymph Nodes in Bronchogenic Carcinoma* Mediastinal Nodal Metastases in Lung Cancer Yoh Watanabe, M.D., F.C.C.P.; ]unzo Shimizu, M.D.; Makoto Tsubota, M.D.; and Takashi
More informationLA RADIOTERAPIA NEL TRATTAMENTO INTEGRATO DEL CANCRO DEL POLMONE NON MICROCITOMA NSCLC I-II
AUSL BA/4 Ospedale S. Paolo Bari U.O. Complessa di Chirurgia Toracica LA RADIOTERAPIA NEL TRATTAMENTO INTEGRATO DEL CANCRO DEL POLMONE NON MICROCITOMA NSCLC I-II stadio L opinione del chirurgo Francesco
More informationcame from a carcinoma and in 12 from a sarcoma. Ninety lesions were intrapulmonary and the as the chest wall and pleura. Details of the primary
Thorax 1982;37:366-370 Thoracic metastases MARY P SHEPHERD From the Thoracic Surgical Unit, Harefield Hospital, Harefield ABSTRACI One hundred and four patients are reviewed who were found to have thoracic
More information24 Ann Thorac Surg 46:24-28, July Copyright by The Society of Thoracic Surgeons
Surgical Management of Lung Cancer with Solitary Cerebral Metastasis John R. Hankins, M.D., John E. Miller, M.D., Michael Salcman, M.D., Frank Ferraro, M.D., David C. Green, M.D., Safuh Attar, M.D., and
More informationCarcinoma of the Lung: A Clinical Review
Carcinoma of the Lung: A Clinical Review R. Samuel Cromartie, 111, M.D., Edward F. Parker, M.D., James E. May, M.D., John S. Metcalf, M.D., and David M. Bartles, M.S. ABSTRACT Records of 702 patients with
More informationP sumed to have early lung disease with a favorable
Survival After Resection of Stage I1 Non-Small Cell Lung Cancer Nael Martini, MD, Michael E. Burt, MD, PhD, Manjit S. Bains, MD, Patricia M. McCormack, MD, Valerie W. Rusch, MD, and Robert J. Ginsberg,
More informationPrognostic value of visceral pleura invasion in non-small cell lung cancer q
European Journal of Cardio-thoracic Surgery 23 (2003) 865 869 www.elsevier.com/locate/ejcts Prognostic value of visceral pleura invasion in non-small cell lung cancer q Jeong-Han Kang, Kil Dong Kim, Kyung
More informationTreatment Strategy for Patients With Surgically Discovered N2 Stage IIIA Non-Small Cell Lung Cancer
Treatment Strategy for Patients With Surgically Discovered N2 Stage IIIA Non-Small Cell Lung Cancer Ryoichi Nakanishi, MD, Toshihiro Osaki, MD, Kozo Nakanishi, MD, Ichiro Yoshino, MD, Takashi Yoshimatsu,
More informationLYMPH NODE METASTASIS IN SMALL PERIPHERAL ADENOCARCINOMA OF THE LUNG
LYMPH NODE METASTASIS IN SMALL PERIPHERAL ADENOCARCINOMA OF THE LUNG Tsuneyo Takizawa, MD a Masanori Terashima, MD a Teruaki Koike, MD a Takehiro Watanabe, MD a Yuzo Kurita, MD b Akira Yokoyama, MD b Keiichi
More informationMEDIASTINAL LYMPH NODE METASTASIS IN PATIENTS WITH CLINICAL STAGE I PERIPHERAL NON-SMALL-CELL LUNG CANCER
MEDIASTINAL LYMPH NODE METASTASIS IN PATIENTS WITH CLINICAL STAGE I PERIPHERAL NON-SMALL-CELL LUNG CANCER Tsuneyo Takizawa, MD a Masanori Terashima, MD a Teruaki Koike, MD a Hideki Akamatsu, MD a Yuzo
More informationAccording to the current International Union
Treatment of Stage II Non-small Cell Lung Cancer* Walter J. Scott, MD, FCCP; John Howington, MD, FCCP; and Benjamin Movsas, MD Based on clinical assessment alone, patients with stage II non-small cell
More informationThe roles of adjuvant chemotherapy and thoracic irradiation
Factors Predicting Patterns of Recurrence After Resection of N1 Non-Small Cell Lung Carcinoma Timothy E. Sawyer, MD, James A. Bonner, MD, Perry M. Gould, MD, Robert L. Foote, MD, Claude Deschamps, MD,
More informationMarcel Th. M. van Rens, MD; Aart Brutel de la Rivière, MD, PhD, FCCP; Hans R. J. Elbers, MD, PhD; and Jules M. M. van den Bosch, MD, PhD, FCCP
Prognostic Assessment of 2,361 Patients Who Underwent Pulmonary Resection for Non-small Cell Lung Cancer, Stage I, II, and IIIA* Marcel Th. M. van Rens, MD; Aart Brutel de la Rivière, MD, PhD, FCCP; Hans
More informationLung cancer involving neighboring structures is classified
GENERAL THORACIC Subcategorization of Resectable Non-Small Cell Lung Cancer Involving Neighboring Structures Noriaki Sakakura, MD, Shoichi Mori, MD, Futoshi Ishiguro, MD, Takayuki Fukui, MD, Shunzo Hatooka,
More informationand Strength of Recommendations
ASTRO with ASCO Qualifying Statements in Bold Italics s patients with T1-2, N0 non-small cell lung cancer who are medically operable? 1A: Patients with stage I NSCLC should be evaluated by a thoracic surgeon,
More informationSurgical Treatment of Lung Cancer with Vertebral Invasion
Original Article Surgical Treatment of Lung Cancer with Vertebral Invasion Kiyoshi Koizumi, MD, Shuji Haraguchi, MD, Tomomi Hirata, MD, Kyoji Hirai, MD, Iwao Mikami, MD, Shigeki Yamagishi, MD, Daisuke
More informationAggressive Slurgical Management of Testicular Carcinoma Metastatic to Lungs and Mediastinurn
Aggressive Slurgical Management of Testicular Carcinoma Metastatic to Lungs and Mediastinurn Isadore Mandelbaum, M.D., Stephen D. Williams, M.D., and Lawrence H. Einhorn, M.D. ABSTRACT During the past
More informationSurgical Treatment for Pulmonary Me. Tsunehisa; Kugimiya, Toshiyasu. Citation Acta medica Nagasakiensia. 1983, 28
NAOSITE: Nagasaki University's Ac Title Author(s) Surgical Treatment for Pulmonary Me Ayabe, Hiroyoshi; Tomita, Masao; Na Katsunobu; Nakao, Susumu; Eguchi, M Tsunehisa; Kugimiya, Toshiyasu Citation Acta
More informationPredicting Postoperative Pulmonary Function in Patients Undergoing Lung Resection*
Predicting Postoperative Pulmonary Function in Patients Undergoing Lung Resection* Bernhardt G. Zeiher, MD; Thomas ]. Gross, MD; Jeffery A. Kern, MD, FCCP; Louis A. Lanza, MD, FCCP; and Michael W. Peterson,
More informationNon-Small Cell Lung Cancer: Disease Spectrum and Management in a Tertiary Care Hospital
Non-Small Cell Lung Cancer: Disease Spectrum and Management in a Tertiary Care Hospital Muhammad Rizwan Khan,Sulaiman B. Hasan,Shahid A. Sami ( Department of Surgery, The Aga Khan University Hospital,
More informationM expected to arise in 1.6% to 3.0% of all patients. Multiple Primary Lung Carcinomas: Prognosis and Treatment
Multiple Primary Lung Carcinomas: Prognosis and Treatment Todd K. Rosengart, MD, Nael Martini, MD, Pierre Ghosn, MD, and Michael Burt, MD, PhD Thoracic Service, Department of Surgery, Memorial-Sloan Kettering
More informationImpact of Radical Systematic Mediastinal Lymphadenectomy on Tumor Staging in Lung Cancer
Impact of Radical Systematic Mediastinal Lymphadenectomy on Tumor Staging in Lung Cancer Jakob R. Izbicki, MD, Bernward Passlick, MD, Ortrud Karg, MD, Christian Bloechle, MD, Klaus Pantel, MD, Wolfram
More informationSuperior and Basal Segment Lung Cancers in the Lower Lobe Have Different Lymph Node Metastatic Pathways and Prognosis
ORIGINAL ARTICLES: Superior and Basal Segment Lung Cancers in the Lower Lobe Have Different Lymph Node Metastatic Pathways and Prognosis Shun-ichi Watanabe, MD, Kenji Suzuki, MD, and Hisao Asamura, MD
More informationInterstitial Irradiation for Unresectable Carcinoma of the Lung
THE ANNALS OF THORACIC SURGERY Journal of The Society of Thoracic Surgeons and the Southern Thoracic Surgical Association VOLUME 20 NUMBER 5 NOVEMBER 1975 Interstitial Irradiation for Unresectable Carcinoma
More informationThe right middle lobe is the smallest lobe in the lung, and
ORIGINAL ARTICLE The Impact of Superior Mediastinal Lymph Node Metastases on Prognosis in Non-small Cell Lung Cancer Located in the Right Middle Lobe Yukinori Sakao, MD, PhD,* Sakae Okumura, MD,* Mun Mingyon,
More informationLymph node dissection for lung cancer is both an old
LOBE-SPECIFIC EXTENT OF SYSTEMATIC LYMPH NODE DISSECTION FOR NON SMALL CELL LUNG CARCINOMAS ACCORDING TO A RETROSPECTIVE STUDY OF METASTASIS AND PROGNOSIS Hisao Asamura, MD Haruhiko Nakayama, MD Haruhiko
More informationBronchial Carcinoma and the Lymphatic Sump: The Importance of Bronchoscopic Findings
Bronchial Carcinoma and the Lymphatic Sump: The Importance of Bronchoscopic Findings Gordon F. Murray, M.D., Ormond C. Mendes, M.D., and Benson R. Wilcox, M.D. ABSTRACT The lymphatic sump of Borrie is
More informationDespite their reputation of benignity, carcinoid tumors
Operative Risk and Prognostic Factors of Typical Bronchial Carcinoid Tumors Xavier Ducrocq, MD, Pascal Thomas, MD, Gilbert Massard, MD, Pierre Barsotti, MD, Roger Giudicelli, MD, Pierre Fuentes, MD, and
More informationTHORACIC MALIGNANCIES
THORACIC MALIGNANCIES Summary for Malignant Malignancies. Lung Ca 1 Lung Cancer Non-Small Cell Lung Cancer Diagnostic Evaluation for Non-Small Lung Cancer 1. History and Physical examination. 2. CBCDE,
More informationBronchogenic Carcinoma
A 55-year-old construction worker has smoked 2 packs of ciggarettes daily for the past 25 years. He notes swelling in his upper extremity & face, along with dilated veins in this region. What is the most
More informationValue of Systematic Mediastinal Lymph Node Dissection During Pulmonary Metastasectomy
Value of Systematic Mediastinal Lymph Node Dissection During Pulmonary Metastasectomy Florian Loehe, MD, Sonja Kobinger, MD, Rudolf A. Hatz, MD, Thomas Helmberger, MD, Udo Loehrs, MD, and Heinrich Fuerst,
More informationPDF hosted at the Radboud Repository of the Radboud University Nijmegen
PDF hosted at the Radboud Repository of the Radboud University Nijmegen The following full text is a publisher's version. For additional information about this publication click this link. http://hdl.handle.net/2066/23566
More informationResults of Chest Wall Resection and Reconstruction With and Without Rigid Prosthesis
ORIGINAL ARTICLES: SURGERY: To participate in The Annals of Thoracic Surgery CME Program, please visit http://cme.ctsnetjournals.org. Results of Chest Wall Resection and Reconstruction With and Without
More informationT3 NSCLC: Chest Wall, Diaphragm, Mediastinum
for T3 NSCLC: Chest Wall, Diaphragm, Mediastinum AATS Postgraduate Course April 29, 2012 Thomas A. D Amico MD Professor of Surgery, Chief of Thoracic Surgery Duke University Health System Disclosure No
More informationPulmonary Resection for Metastases from Colorectal Cancer
ORIGINAL ARTICLE Pulmonary Resection for Metastases from Colorectal Cancer Paul M. van Schaik, MD,* Ewout A. Kouwenhoven, MD, PhD,* Robert J. Bolhuis, MD,* Bonne Biesma, MD, PhD, and Koop Bosscha, MD,
More informationComplex Thoracoscopic Resections for Locally Advanced Lung Cancer
Complex Thoracoscopic Resections for Locally Advanced Lung Cancer Duke Thoracoscopic Lobectomy Workshop March 21, 2018 Thomas A. D Amico MD Gary Hock Professor of Surgery Section Chief, Thoracic Surgery,
More informationFactors affecting survival in non-small cell lung cancer invading the chest wall.
Biomedical Research 2017; 28 (6): 2673-2678 ISSN 0970-938X www.biomedres.info Factors affecting survival in non-small cell lung cancer invading the chest wall. Abidin Sehitogullari 1, Yusuf Aydemir 2*,
More informationComplete surgical excision remains the greatest potential
ORIGINAL ARTICLE Wedge Resection for Non-small Cell Lung Cancer in Patients with Pulmonary Insufficiency: Prospective Ten-Year Survival John P. Griffin, MD,* Charles E. Eastridge, MD, Elizabeth A. Tolley,
More informationCase presentation. Paul De Leyn, MD, PhD Thoracic Surgery University Hospitals Leuven Belgium
Case presentation Paul De Leyn, MD, PhD Thoracic Surgery University Hospitals Leuven Belgium Perspectives in Lung Cancer Brussels 6-7 march 2009 LEUVEN LUNG CANCER GROUP Department of Thoracic Surgery
More informationMolly Boyd, MD Glenn Mills, MD Syed Jafri, MD 1/1/2010
LSU HEALTH SCIENCES CENTER NSCLC Guidelines Feist-Weiller Cancer Center Molly Boyd, MD Glenn Mills, MD Syed Jafri, MD 1/1/2010 Initial Evaluation/Intervention: 1. Pathology Review 2. History and Physical
More information141 Ann Thorac Surg , Aug Copyright by The Society of Thoracic Surgeons
Completion Pneumonectomy: Indications, Complications, and Results Eilis M. McGovern, M.B.B.Ch., Victor F. Trastek, M.D., Peter C. Pairolero, M.D., and W. Spencer Payne, M.D. ABSTRACT From 958 through 985,
More informationAlthough the international TNM classification system
Prognostic Significance of Perioperative Serum Carcinoembryonic Antigen in Non-Small Cell Lung Cancer: Analysis of 1,000 Consecutive Resections for Clinical Stage I Disease Morihito Okada, MD, PhD, Wataru
More informationSlide 1. Slide 2. Slide 3. Investigation and management of lung cancer Robert Rintoul. Epidemiology. Risk factors/aetiology
Slide 1 Investigation and management of lung cancer Robert Rintoul Department of Thoracic Oncology Papworth Hospital Slide 2 Epidemiology Second most common cancer in the UK (after breast). 38 000 new
More informationChest Wall Tumors and Reconstruction: Lateral Chest Wall. Dr. Robert Kelly
Chest Wall Tumors and Reconstruction: Lateral Chest Wall Dr. Robert Kelly THORACIC PROGRAMME: ADVANCES IN CHEST WALL SURGERY AND OSTEOSYNTHESIS Dr. José Ribas Milanez de Campos Assistant, Professor, Department
More informationChemotherapy for Adenocarcinoma and Alveolar Cell Carcinoma
Chemotherapy for Adenocarcinoma and Alveolar Cell Carcinoma of the Lung Scott L. Faulkner, M.D., R. Benton Adkins, Jr., M.D., and Vernon H. Reynolds, M.D. ABSTRACT Ten patients with inoperable or recurrent
More informationTreatment of Inoperable Lung Carcinoma: A Combined Modality Approach
Treatment of Inoperable ung Carcinoma: A Combined Modality Approach Hiroshi Takita, M.D., Ariel C. Hollinshead, h.d., Donna J. Rizzo, R.N., Christine M. Kramer, M.S., Tah Y. Chen, M.D., Joginder N. Bhayana,
More informationLung cancer with chest wall involvement: Predictive factors of long-term survival after surgical resection
Lung Cancer (2006) 52, 359 364 available at www.sciencedirect.com journal homepage: www.elsevier.com/locate/lungcan Lung cancer with chest wall involvement: Predictive factors of long-term survival after
More informationAfter primary tumor treatment, 30% of patients with malignant
ESTS METASTASECTOMY SUPPLEMENT Alberto Oliaro, MD, Pier L. Filosso, MD, Maria C. Bruna, MD, Claudio Mossetti, MD, and Enrico Ruffini, MD Abstract: After primary tumor treatment, 30% of patients with malignant
More informationRegion: 11. Clinic6patholo cal Studies
Tumors of the Thvmus and ThVIIliC Region: 11. Clinic6patholo cal Studies on Hodgkin s Disease of Re Thymus N. P. Bergh, M.D., P. Gatzinsky, M.D., S. Larsson, M.D., P. Lundin, M.D., and B. Ridell, M.D.
More informationB number of patients who have received conventional
FULL THICKNESS CHEST WALL RESECTION FOR RECURRENT BREAST CARCINOMA INVOLVING THE BONY CHEST WALL JATIN P. SHAH, MD, AND JEROME A. URBAN, MD Solitary recurrent breast cancer involving the bony chest wall
More informationLung cancer pleural invasion was recognized as a poor prognostic
Visceral pleural invasion classification in non small cell lung cancer: A proposal on the basis of outcome assessment Kimihiro Shimizu, MD a Junji Yoshida, MD a Kanji Nagai, MD a Mitsuyo Nishimura, MD
More informationRevisit of Primary Malignant Neoplasms of the Trachea: Clinical Characteristics and Survival Analysis
Jpn J Clin Oncol 1997;27(5)305 309 Revisit of Primary Malignant Neoplasms of the Trachea: Clinical Characteristics and Survival Analysis -, -, - - 1 Chest Department and 2 Section of Thoracic Surgery,
More informationShort- and Long-Term Outcomes after Pneumonectomy for Primary Lung Cancer
Original Article Short- and Long-Term Outcomes after Pneumonectomy for Primary Lung Cancer Takeshi Kawaguchi, MD, Takashi Tojo, MD, Keiji Kushibe, MD, Michitaka Kimura, MD, Yoko Nagata, MD, and Shigeki
More informationwith Preoperative and Postoperative Radiotherapy
Pancoast Tumors: Improved Survival with Preoperative and Postoperative Radiotherapy David M. Shahian, M.D., Wilford B. Neptune, M.D., and F. Henry Ellis, Jr., M.D., Ph.D. ABSTRACT Long-term survival after
More informationRoutine reinforcement of bronchial stump after lobectomy or pneumonectomy with pedicled pericardial flap (PPF)
Routine reinforcement of bronchial stump after lobectomy or pneumonectomy with pedicled pericardial flap (PPF) Abstract The results of 25 cases underwent a pedicled pericardial flap coverage for the bronchial
More informationThoracoplasty for the Management of Postpneumonectomy Empyema
ISPUB.COM The Internet Journal of Thoracic and Cardiovascular Surgery Volume 9 Number 2 Thoracoplasty for the Management of Postpneumonectomy Empyema S Mullangi, G Diaz-Fuentes, S Khaneja Citation S Mullangi,
More informationThe tumor, node, metastasis (TNM) staging system of lung
ORIGINAL ARTICLE Peripheral Direct Adjacent Lobe Invasion Non-small Cell Lung Cancer Has a Similar Survival to That of Parietal Pleural Invasion T3 Disease Hao-Xian Yang, MD, PhD,* Xue Hou, MD, Peng Lin,
More informationPULMONARY RESECTION FOR METASTATIC COLORECTAL CANCER: EXPERIENCES WITH 159 PATIENTS
PULMONARY RESECTION FOR METASTATIC COLORECTAL CANCER: EXPERIENCES WITH 159 PATIENTS Shinji Okumura, MD Haruhiko Kondo, MD Masahiro Tsuboi, MD Haruhiko Nakayama, MD Hisao Asamura, MD Ryosuke Tsuchiya, MD
More informationStandard treatment for pulmonary metastasis of non-small
ORIGINAL ARTICLE Resection of Pulmonary Metastasis of Non-small Cell Lung Cancer Kenichi Okubo, MD,* Toru Bando, MD,* Ryo Miyahara, MD,* Hiroaki Sakai, MD,* Tsuyoshi Shoji, MD,* Makoto Sonobe, MD,* Takuji
More informationCase Scenario 1. Pathology report Specimen from mediastinoscopy Final Diagnosis : Metastatic small cell carcinoma with residual lymphatic tissue
Case Scenario 1 Oncology Consult: Patient is a 51-year-old male with history of T4N3 squamous cell carcinoma of tonsil status post concurrent chemoradiation finished in October two years ago. He was hospitalized
More informationminimally invasive techniques
minimally invasive techniques En Bloc Minimal Laser Resection for T3-Chest Wall Lung Cancer in Patients With Poor Pulmonary Function* Tommaso Claudio Mineo, MD; Vincenzo Amhrogi, MD; Eugenio Pompeo, MD;
More information1/25/13 Right partial nephrectomy followed by completion right radical nephrectomy.
History and Physical Case Scenario 1 45 year old white male presents with complaints of nausea, weight loss, and back pain. A CT of the chest, abdomen and pelvis was done on 12/8/12 that revealed a 12
More informationPrognostic Factors for Survival of Stage IB Upper Lobe Non-small Cell Lung Cancer Patients: A Retrospective Study in Shanghai, China
www.springerlink.com Chin J Cancer Res 23(4):265 270, 2011 265 Original Article Prognostic Factors for Survival of Stage IB Upper Lobe Non-small Cell Lung Cancer Patients: A Retrospective Study in Shanghai,
More informationThoracic Surgery; An Overview
Thoracic Surgery What we see Thoracic Surgery; An Overview James P. Locher, Jr, MD Methodist Cardiovascular and Thoracic Surgery Lung cancer Mets Fungus and TB Lung abcess and empyema Pleural based disease
More informationSurgical Approaches to Pulmonary Metastases
Surgical Approaches to Pulmonary Metastases Raja M Flores MD Professor and Chief Thoracic Surgery Mount Sinai School of Medicine New York, New York History of Lung Metastasectomy 1882 Weinlechner +CW 1926
More informationThoracoscopic Lobectomy for Locally Advanced Lung Cancer. Masters of Minimally Invasive Thoracic Surgery Orlando September 19, 2014
for Locally Advanced Lung Cancer Masters of Minimally Invasive Thoracic Surgery Orlando September 19, 2014 Thomas A. D Amico MD Gary Hock Endowed Professor and Vice Chair of Surgery Chief Thoracic Surgery
More informationRadiation-Induced Soft-Tissue Fibrosarcoma: Surgical Therapy and Salvage
Radiation-Induced Soft-Tissue Fibrosarcoma: Surgical Therapy and Salvage M. B. O Neil, Jr., M.D., William Cocke, M.D., Duncan Mason, M.D., and Edward J. Hurley, M.D. ABSTRACT Soft-tissue fibrosarcomas
More informationL cancer-related deaths in Japan. The number of patients
Extended Resection of the Left Atrium, Great Vessels, or Both for Lung Cancer Ryosuke Tsuchiya, MD, Hisao Asamura, MD, Haruhiko Kondo, MD, Tomoyuki Goya, MD, and Tsuguo Naruke, MD Division of Thoracic
More informationLung Cancer Imaging. Terence Z. Wong, MD,PhD. Department of Radiology Duke University Medical Center Durham, NC 9/9/09
Lung Cancer Imaging Terence Z. Wong, MD,PhD Department of Radiology Duke University Medical Center Durham, NC 9/9/09 Acknowledgements Edward F. Patz, Jr., MD Jenny Hoang, MD Ellen L. Jones, MD, PhD Lung
More informationEARLY AND LONG-TERM RESULTS OF PROSTHETIC CHEST WALL RECONSTRUCTION
EARLY AND LONG-TERM RESULTS OF PROSTHETIC CHEST WALL RECONSTRUCTION Claude Deschamps, MD Bulent Mehmit Tirnaksiz, MD Ramin Darbandi Victor F. Trastek, MD Mark S. Allen, MD Daniel L. Miller, MD Phillip
More informationNew lung lesion in a 55 year-old male treated with chemoradiation for non-small cell lung carcinoma
July 2016 New lung lesion in a 55 year-old male treated with chemoradiation for non-small cell lung carcinoma Contributed by: Laurel Rose, MD, Resident Physician, Indiana University School of Medicine,
More informationCollaborative Stage. Site-Specific Instructions - LUNG
Slide 1 Collaborative Stage Site-Specific Instructions - LUNG In this presentation, we are going to review the AJCC Cancer Staging criteria for the lung primary site. Slide 2 Reading Assignments As each
More informationPrimary Cancer of the Lung
Primary Cancer of the Lung A 42-Year Experience Richard H. Overholt, M.D., Wilford B. Neptune, M.D., and Mian M. Ashraf, M.D. ABSTRACT Between April, 1932, and July, 1974,3,808 patients with primary lung
More informationCombined chemotherapy and Radiotherapy for Patients with Breast Cancer and Extensive Nodal Involvement.
Combined chemotherapy and Radiotherapy for Patients with Breast Cancer and Extensive Nodal Involvement. Ung O, Langlands A, Barraclough B, Boyages J. J Clin Oncology 13(2) : 435-443, Feb 1995 STUDY DESIGN
More informationLung Cancer Clinical Guidelines: Surgery
Lung Cancer Clinical Guidelines: Surgery 1 Scope of guidelines All Trusts within Manchester Cancer are expected to follow this guideline. This guideline is relevant to: Adults (18 years and older) with
More informationIndex. Note: Page numbers of article titles are in boldface type.
Note: Page numbers of article titles are in boldface type. A Ablative therapy, nonsurgical, for pulmonary metastases of soft tissue sarcoma, 279 280 Adipocytic tumors, atypical lipomatous tumor vs. well-differentiated
More informationClinical significance of skipping mediastinal lymph node metastasis in N2 non-small cell lung cancer
Original Article Clinical significance of skipping mediastinal lymph node metastasis in N2 non-small cell lung cancer Jun Zhao*, Jiagen Li*, Ning Li, Shugeng Gao Department of Thoracic Surgery, National
More informationPulmonary Metastasectomy for Pulmonary Metastases of Head and Neck Squamous Cell Carcinomas
ORIGINAL ARTICLES: SURGERY: The Annals of Thoracic Surgery CME Program is located online at http://cme.ctsnetjournals.org. To take the CME activity related to this article, you must have either an STS
More informationThe Importance of One-Stage Median Stemotomy and Retroperitoneal Node Dissection in Disseminated Testicular Cancer
The Importance of One-Stage Median Stemotomy and Retroperitoneal Node Dissection in Disseminated Testicular Cancer Isidore Mandelbaum, M.D., Peter B. Yaw, M.D., Lawrence H. Einhorn, M.D., Stephen D. Williams,
More informationAlthough ipsilateral intrapulmonary metastasis (PM), Evaluation of TMN Classification for Lung Carcinoma With Ipsilateral Intrapulmonary Metastasis
Evaluation of TMN Classification for Lung Carcinoma With Ipsilateral Intrapulmonary Metastasis Morihito Okada, MD, Noriaki Tsubota, MD, Masahiro Yoshimura, MD, Yoshifumi Miyamoto, MD, and Reiko Nakai,
More informationN.E. Verstegen A.P.W.M. Maat F.J. Lagerwaard M.A. Paul M.I. Versteegh J.J. Joosten. W. Lastdrager E.F. Smit B.J. Slotman J.J.M.E. Nuyttens S.
N.E. Verstegen A.P.W.M. Maat F.J. Lagerwaard M.A. Paul M.I. Versteegh J.J. Joosten W. Lastdrager E.F. Smit B.J. Slotman J.J.M.E. Nuyttens S.Senan Submitted 10 Salvage surgery for local failures after stereotactic
More informationCharles Mulligan, MD, FACS, FCCP 26 March 2015
Charles Mulligan, MD, FACS, FCCP 26 March 2015 Review lung cancer statistics Review the risk factors Discuss presentation and staging Discuss treatment options and outcomes Discuss the status of screening
More informationEVIDENCE BASED MANAGEMENT OF STAGE III NSCLC MILIND BALDI
EVIDENCE BASED MANAGEMENT OF STAGE III NSCLC MILIND BALDI Overview Introduction Diagnostic work up Treatment Group 1 Group 2 Group 3 Stage III lung cancer Historically was defined as locoregionally advanced
More informationAdjuvant Chemotherapy in High Risk Patients after Wertheim Hysterectomy 10-year Survivals
6 Adjuvant Chemotherapy in High Risk Patients after Wertheim Hysterectomy 0-year Survivals V Sivanesaratnam,*FAMM, FRCOG, FACS Abstract Although the primary operative mortality following radical hysterectomy
More informationClinical Staging and the Tendency of Malignant Pleural Mesotheliomas to Remain Localized
Clinical Staging and the Tendency of Malignant Pleural Mesotheliomas to Remain Localized Russell J. Nauta, M.D., Robert T. Osteen, M.D., Karen H. Antman, M.D., and J. Kenneth Koster, M.D. ABSTRACT Thirty-two
More informationExtended Resection of Chest Wall Tumors with Reconstruction Using Poly Methyl Methacrylate-Mesh Prosthesis
Journal of the Egyptian Nat. Cancer Inst., Vol. 5, No., June: 45-54, 00 Extended Resection of Chest Wall Tumors with Reconstruction Using Poly Methyl Methacrylate-Mesh Prosthesis MOHAMAD ABO SEDIRA, M.D.*;
More informationAmerican Journal ofcancer Case Reports
American Journal ofcancer Case Reports http://ivyunion.org/index.php/ajccr/ Fracasso JI et al. American Journal of Cancer Case Reports 2018, 6:25-30 Page 1 of 6 Case Report Chondrosarcoma of the Sternum
More informationPrimary Tumors of Ribs
Primary Tumors of Ribs Frank E. Schmidt, M.D., and Max J. Trummer, Capt, MC, USN ABSTRACT An analysis of 50 consecutive patients with primary rib tumors operated on at the U.S. Naval Hospital, San Diego,
More informationAn Update: Lung Cancer
An Update: Lung Cancer Andy Barlow Consultant in Respiratory Medicine Lead Clinician for Lung Cancer (West Herts Hospitals NHS Trust) Lead for EBUS-Harefield Hospital (RB&HFT) Summary Lung cancer epidemiology
More informationMediastinal Staging. Samer Kanaan, M.D.
Mediastinal Staging Samer Kanaan, M.D. Overview Importance of accurate nodal staging Accuracy of radiographic staging Mediastinoscopy EUS EBUS Staging TNM Definitions T Stage Size of the Primary Tumor
More information